Solid Tumors
Conditions
Interventions
investigational material(s)
Generic name etc : Avelumab(MSB0010718C)
INN of investigational material : Avelumab
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Inv
Sponsors
Merck Biopharma Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Signed written informed consent Male or female subjects aged greater than or equal to 20 years. For dose escalation part Histologically or cytologically proven metastatic or locally advanced solid tumors, for which no standard therapy exists or standard therapy has failed For expansion part Availability of fresh and archive tumor in formalin fixedparaffin embedded tissue With histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] 7th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinum. Presence of at least 1 measurable lesion according to RECIST version 1.1 Subjects should not have severe peritoneal metastases. The following criteria were applied: -No clinical ileus or subileus -No moderate-to-severe ascites (subjects with ascites restricted to the perihepatic space or pelvic cavity) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the trial entry and an estimated life expectancy of at least 3 months Adequate hematological, hepatic and renal function as defined in the protocol All subjects must agree to use effective means of contraception with their partner from entry into the trial through 6 months after the last dose of avelumab
Exclusion criteria
Exclusion criteria: -Concurrent treatment with a non-permitted drug -Prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints) -Concurrent anticancer treatment or concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 30 days before the start of trial treatment. Short-term administration of steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) is allowed -Previous malignant disease within the last 5 years with the exception of adequately treated non-melanoma skin cancer, in situ cancer, or other cancer -Non-oncology vaccine therapies for prevention of infection disease (e.g. seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. -Pregnancy or lactation period -Known alcohol or drug abuse -Clinically significant (that is, active) cardiovascular disease -All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment -Any psychiatric condition that would prohibit the understanding or rendering of informed consent -Legal incapacity or limited legal capacity -Other protocol defined exclusion criteria could apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety Dose Limiting Toxicity [ Time Frame: Up to 3 weeks ] | — |
Secondary
| Measure | Time frame |
|---|---|
| safety -Pharmacokinetic prifile -Expression profile of PD-L1 in tumor tissues evaluated by immunohistochemistry -Exploration of molecular,cellular and soluble markers for example, but not limited to, changes in receptor ocupancy and cytokine levels that may be relevant to the mechanism of action of, or response/resistance to Avelumab -BOR and PFS time according to RECIST 1.1 criteria -irBOR and irPFS time according to RECIST 1.1 criteria -OS time -Serum titers, isotypes, and neutralizing capacity of anti-Avelumab antibodies -Frequency and types of TEAEs according to the NCI-CTCAE v4.0 | — |
Countries
Japan
Outcome results
None listed